Agam Upadhyay Email Address

Founded in 2010, TESARO is a privately held oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates| and to commercialize safer and more effective products for the treatment and support of cancer patients. Since its founding, TESARO has made substantial progress toward building a leading oncology-focused pipeline. In December 2010, the Company announced that it had in-licensed its first product, rolapitant, from OPKO Health, Inc. Rolapitant is a Phase 3-ready neurokinin-1 (NK1) receptor antagonist being developed for the prevention of chemotherapy-induced nausea and vomiting (CINV). In March 2011, TESARO announced that it had in-licensed small molecule inhibitors of Anaplastic Lymphoma Kinase (ALK) from Amgen Inc. that have promising potency, selectivity and pharmaceutical properties. The ALK program represents a molecularly targeted approach to treating certain cancer sub-populations. TESARO plans to develop one or more compounds for oncology indications, including the treatment of patients with non-small cell lung cancer (NSCLC) whose tumors express an ALK fusion protein| recent clinical proof-of-concept has been demonstrated for ALK inhibition in this patient population. The Series B financing will fund further development of these programs and expansion of the pipeline. In May 2010, NEA and TESARO management funded an initial $20 million Series A financing to facilitate the Company's acquisition, development and commercialization of a portfolio of oncology and supportive care products. In June 2011, TESARO announced that it secured $101 million in a Series B financing to advance and expand the Company's cancer product portfolio. Participants included founding investor New Enterprise Associates (NEA) and new investors: InterWest Partners, Kleiner Perkins Caufield & Byers (KPCB), Venrock, Pappas Ventures, T. Rowe Price, Oracle Partners, Deerfield Management and Leerink Swann. NEA is the largest investor in the Series B financing. TESARO was co-founded by former executives of MGI PHARMA, an oncology and acute-care focused biopharmaceutical company that Eisai Co., Ltd. acquired in 2008 for $3.9 billion. TESARO is headquartered in Waltham, Massachusetts.

Results-focused strategic leader with experience in large scale Digital transformation to meet fast evolving business needs, built and managed high performing global diverse teams with utmost focus on execution. Extensive experience in Architecture, designing and managing complex Tech, Cyber Security and Business Platforms in large global environment with domain expertise in health life science, Finance and Consulting sectors. Hands-on experience in negotiating large and complex supplier contracts. Leader that drives sense of urgency, change agent, critical thinking and drive operational excellence along with large scale innovation. Setting up the visionary technology roadmap and delivering it for the organization. Proven ability to manage teams through evolving organizational changes while maintaining high levels of service. Drive the cost efficiency and labor optimization through automation and elimination of work. Ability to adjust and manage multiple demands, priorities and event escalations. Managed large mission critical 24x7 global data centers operational tasks in the incorporation of ITIL methodologies along with managing massive Disaster Recovery and Cyber Security events. Implemented Dev/Ops and Agile operating model. Extensive experience with offshore vendors and resource management to outsource or co-source services. Numerous years of experience in building service based, customer centric culture. Outstanding management, financial, organizational and decision-making skills with a focus on creating enterprise vision and delivering new services to enhance technology offerings for business growth while reducing operational costs. Extensive experience in merger and divestiture including building a playbook. Agile approach in solving business problems, build best in class operating model and Org.